Lancet Diabetes Endocrinol:识别英格兰体重和 BMI 变化高风险的成年人——一项使用电子健康记录的纵向、大规模、基于人群的队列研究

2021-11-09 Naomii MedSci原创

成人肥胖预防政策在很大程度上没有针对性,但在全球范围内成效有限。 需要彻底转变政策,将重点放在体重增加风险最高的个人(即18-24岁的年轻人)身上,在个人和人口层面预防肥胖及其对健康和医疗保健长期后果

      成人肥胖预防政策在很大程度上没有针对性,但在全球范围内成效有限,肥胖症的高流行率预计在未来十年将大幅增加。如果能够利用国家公共卫生系统中现成的信息确定体重增加风险最高的人群,则可以通过新的有针对性的方法来补充全人口预防肥胖症的方法。当前的肥胖预防政策是根据横断面人口调查的证据制定的,从定义上讲,这些调查无法评估体重变化,并突出了中年肥胖症横截面患病率的增加。居住在社会贫困地区的人,特别是少数民族的纵向研究表明,年轻人在许多研究中,比老年人有更大的体重增加风险。

      识别体重增加高危人群的新兴数据科学机会来自纵向基于人群的电子健康记录(EHR)。如果要考虑有针对性的政策,了解成年人的年龄、性别、种族、地理区域和社会剥夺程度如何共同影响体重变化的风险,以确定体重增加风险最高的群体是至关重要的。之前的研究没有提供这样的证据。基于人口的EHR提供了体重和BMI变化的有效测量,它们具有潜在优势(与商定的队列研究相比),有足够的规模来评估几个因素的联合贡献,并提供可更新和低成本的测量。

      近日,有研究使用以人口为基础的EHR来应对长期呼吁在体重变化的背景下监测基本人口体重数据,根据社会人口学因素呈现BMI变化的个体内部1年、5年和10年的模式。目的如下:(1)测试EHR和调查方法之间1998至2016年间平均BMI变化的时间趋势的复制程度;(2)比较BMI变化在各年龄组和BMI类别中的变化幅度和分布;(3)评估年龄、性别、社会剥夺程度、种族和地理区域与BMI类别转换之间的关系; (4)制作风险计算器(在线和图表形式),显示这些风险因素如何组合在一起,以识别转换到较高BMI类别的高危人群

      在这项纵向的基于人群队列研究中,研究使用了来自英国400家初级保健诊所(通过临床实践研究数据链接)的相关EHR数据,这些数据是通过Caliber计划获得的。符合条件的参与者年龄在18-74岁之间,在全科诊所注册,并在1998年1月1日至2016年6月30日期间记录了BMI和体重测量,在此期间,他们拥有合格的关联数据,并进行了至少1年的随访。计算了BMI在1、5和10年期间的纵向变化,并调查了世卫组织定义的BMI类别(体重不足、正常体重、超重、肥胖1级和2级,以及严重肥胖[3级])之间转换的绝对风险和优势比(OR)。通过Logistic回归分析,调整基线BMI、血管疾病家族史、利尿剂的使用和流行的慢性病,评估人口因素与BMI转变的相关性。

  •  研究纳入了2092260名符合条件的个体,他们的BMI测量值超过900万。
  • 在随访1、5和10年时,年轻人年龄是体重增加的最大危险因素。
  • 与年龄最大的年龄组(65~74岁)相比,最小年龄组(18~24岁)的成年人在10岁时从正常体重转变为超重或肥胖的OR最高(4.22[95%CI 3·86~4.62]),绝对危险度最大(37%比24%)。
  • 同样,基线超重或肥胖的最年轻年龄组的成年人转变为更高BMI类别的风险也最高;从超重转变为1级和2级肥胖的OR4·60(4·06-5·22)和绝对风险(42%比18%),以及从1级和2级肥胖转变为3级肥胖的OR5·87(5·23-6·59)和绝对风险(22%比5%)。
  • 其他人口统计学因素与这些转变的关联一直较弱;例如,生活在社会贫困程度最高和最贫困地区的人从正常体重转变为超重或肥胖的OR为1.23(1.18-1.27),男性和女性的OR为1.12(1.08-1.16),黑人和白人的OR为1.13(1.04-1.24)。
  • 研究提供了一个开放访问的在线风险计算器,并提供了1年、5年和10年随访期间的高分辨率肥胖风险图表。

      需要彻底转变政策,将重点放在体重增加风险最高的个人(即18-24岁的年轻人)身上,在个人和人口层面预防肥胖及其对健康和医疗保健的长期后果。

文献来源:https://pubmed.80599.net/34481555/

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1902663, encodeId=c9811902663ea, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Sep 30 20:02:01 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862179, encodeId=fd5d18621e987, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Wed Sep 07 00:02:01 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639944, encodeId=068b163994446, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Apr 01 23:02:01 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761747, encodeId=34041e617470b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 06 16:02:01 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043465, encodeId=d6a320434655a, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Mar 26 03:02:01 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831386, encodeId=bae0183138621, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Feb 28 12:02:01 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455838, encodeId=d95814558386e, content=<a href='/topic/show?id=d740e00417d' target=_blank style='color:#2F92EE;'>#电子健康记录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70041, encryptionId=d740e00417d, topicName=电子健康记录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ffe5741537, createdName=wrj0123, createdTime=Wed Nov 10 14:02:01 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068639, encodeId=795a10686390e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10535696732, createdName=ms3000001187980190, createdTime=Tue Nov 09 16:48:02 CST 2021, time=2021-11-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1902663, encodeId=c9811902663ea, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Sep 30 20:02:01 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862179, encodeId=fd5d18621e987, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Wed Sep 07 00:02:01 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639944, encodeId=068b163994446, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Apr 01 23:02:01 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761747, encodeId=34041e617470b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 06 16:02:01 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043465, encodeId=d6a320434655a, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Mar 26 03:02:01 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831386, encodeId=bae0183138621, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Feb 28 12:02:01 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455838, encodeId=d95814558386e, content=<a href='/topic/show?id=d740e00417d' target=_blank style='color:#2F92EE;'>#电子健康记录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70041, encryptionId=d740e00417d, topicName=电子健康记录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ffe5741537, createdName=wrj0123, createdTime=Wed Nov 10 14:02:01 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068639, encodeId=795a10686390e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10535696732, createdName=ms3000001187980190, createdTime=Tue Nov 09 16:48:02 CST 2021, time=2021-11-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1902663, encodeId=c9811902663ea, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Sep 30 20:02:01 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862179, encodeId=fd5d18621e987, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Wed Sep 07 00:02:01 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639944, encodeId=068b163994446, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Apr 01 23:02:01 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761747, encodeId=34041e617470b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 06 16:02:01 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043465, encodeId=d6a320434655a, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Mar 26 03:02:01 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831386, encodeId=bae0183138621, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Feb 28 12:02:01 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455838, encodeId=d95814558386e, content=<a href='/topic/show?id=d740e00417d' target=_blank style='color:#2F92EE;'>#电子健康记录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70041, encryptionId=d740e00417d, topicName=电子健康记录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ffe5741537, createdName=wrj0123, createdTime=Wed Nov 10 14:02:01 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068639, encodeId=795a10686390e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10535696732, createdName=ms3000001187980190, createdTime=Tue Nov 09 16:48:02 CST 2021, time=2021-11-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1902663, encodeId=c9811902663ea, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Sep 30 20:02:01 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862179, encodeId=fd5d18621e987, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Wed Sep 07 00:02:01 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639944, encodeId=068b163994446, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Apr 01 23:02:01 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761747, encodeId=34041e617470b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 06 16:02:01 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043465, encodeId=d6a320434655a, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Mar 26 03:02:01 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831386, encodeId=bae0183138621, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Feb 28 12:02:01 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455838, encodeId=d95814558386e, content=<a href='/topic/show?id=d740e00417d' target=_blank style='color:#2F92EE;'>#电子健康记录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70041, encryptionId=d740e00417d, topicName=电子健康记录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ffe5741537, createdName=wrj0123, createdTime=Wed Nov 10 14:02:01 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068639, encodeId=795a10686390e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10535696732, createdName=ms3000001187980190, createdTime=Tue Nov 09 16:48:02 CST 2021, time=2021-11-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1902663, encodeId=c9811902663ea, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Sep 30 20:02:01 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862179, encodeId=fd5d18621e987, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Wed Sep 07 00:02:01 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639944, encodeId=068b163994446, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Apr 01 23:02:01 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761747, encodeId=34041e617470b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 06 16:02:01 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043465, encodeId=d6a320434655a, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Mar 26 03:02:01 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831386, encodeId=bae0183138621, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Feb 28 12:02:01 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455838, encodeId=d95814558386e, content=<a href='/topic/show?id=d740e00417d' target=_blank style='color:#2F92EE;'>#电子健康记录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70041, encryptionId=d740e00417d, topicName=电子健康记录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ffe5741537, createdName=wrj0123, createdTime=Wed Nov 10 14:02:01 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068639, encodeId=795a10686390e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10535696732, createdName=ms3000001187980190, createdTime=Tue Nov 09 16:48:02 CST 2021, time=2021-11-09, status=1, ipAttribution=)]
    2022-03-26 ylz8403
  6. [GetPortalCommentsPageByObjectIdResponse(id=1902663, encodeId=c9811902663ea, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Sep 30 20:02:01 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862179, encodeId=fd5d18621e987, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Wed Sep 07 00:02:01 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639944, encodeId=068b163994446, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Apr 01 23:02:01 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761747, encodeId=34041e617470b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 06 16:02:01 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043465, encodeId=d6a320434655a, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Mar 26 03:02:01 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831386, encodeId=bae0183138621, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Feb 28 12:02:01 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455838, encodeId=d95814558386e, content=<a href='/topic/show?id=d740e00417d' target=_blank style='color:#2F92EE;'>#电子健康记录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70041, encryptionId=d740e00417d, topicName=电子健康记录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ffe5741537, createdName=wrj0123, createdTime=Wed Nov 10 14:02:01 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068639, encodeId=795a10686390e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10535696732, createdName=ms3000001187980190, createdTime=Tue Nov 09 16:48:02 CST 2021, time=2021-11-09, status=1, ipAttribution=)]
    2022-02-28 howi
  7. [GetPortalCommentsPageByObjectIdResponse(id=1902663, encodeId=c9811902663ea, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Sep 30 20:02:01 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862179, encodeId=fd5d18621e987, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Wed Sep 07 00:02:01 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639944, encodeId=068b163994446, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Apr 01 23:02:01 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761747, encodeId=34041e617470b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 06 16:02:01 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043465, encodeId=d6a320434655a, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Mar 26 03:02:01 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831386, encodeId=bae0183138621, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Feb 28 12:02:01 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455838, encodeId=d95814558386e, content=<a href='/topic/show?id=d740e00417d' target=_blank style='color:#2F92EE;'>#电子健康记录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70041, encryptionId=d740e00417d, topicName=电子健康记录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ffe5741537, createdName=wrj0123, createdTime=Wed Nov 10 14:02:01 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068639, encodeId=795a10686390e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10535696732, createdName=ms3000001187980190, createdTime=Tue Nov 09 16:48:02 CST 2021, time=2021-11-09, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1902663, encodeId=c9811902663ea, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Sep 30 20:02:01 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862179, encodeId=fd5d18621e987, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Wed Sep 07 00:02:01 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639944, encodeId=068b163994446, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Apr 01 23:02:01 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761747, encodeId=34041e617470b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 06 16:02:01 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043465, encodeId=d6a320434655a, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Mar 26 03:02:01 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831386, encodeId=bae0183138621, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Feb 28 12:02:01 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455838, encodeId=d95814558386e, content=<a href='/topic/show?id=d740e00417d' target=_blank style='color:#2F92EE;'>#电子健康记录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70041, encryptionId=d740e00417d, topicName=电子健康记录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ffe5741537, createdName=wrj0123, createdTime=Wed Nov 10 14:02:01 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068639, encodeId=795a10686390e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10535696732, createdName=ms3000001187980190, createdTime=Tue Nov 09 16:48:02 CST 2021, time=2021-11-09, status=1, ipAttribution=)]
    2021-11-09 ms3000001187980190

    学习

    0

相关资讯

Br J Cancer:丹麦国家膳食指南与结直肠癌发病风险的相关性研究

结直肠癌 (CRC) 作为全球三大最常见的癌症之一,在2018年有超过120万的新确诊病例以及608,700的死亡病例。

超20万人研究:用抗生素一时爽,糖尿病风险蹭蹭涨?

Scientifc Reports:在韩国进行的具有全国代表性的回顾性队列研究中,抗生素使用与糖尿病发病率之间的关联

JAAD:异维A酸治疗肥胖和超重青年的痤疮时需要调整剂量吗?

有关异维A酸治疗肥胖和超重年轻人的痤疮研究较少。研究结果表明,目前的治疗策略对超重和肥胖的年轻人来说是适宜和安全的。

Nature Metabolism:味精导致肥胖?研究揭示味精诱导肥胖的具体机制

谷氨酸钠是味精的主要成分,也是构成人体的基本氨基酸。因此,从生理角度来推断,味精并不会给健康带来不利影响。但一直以来,围绕味精的争议和质疑却十分多,事实到底如何呢?

Eur Respir J:中国人群大规模全基因组关联分析发现肺功能的新位点

这项大规模的肺功能GWAS确定了肺功能和肥胖之间的新基因位点和共同的遗传病因学。

超18万人研究发现:避孕药或降低多囊卵巢综合征女性患 2 型糖尿病的风险

每10名妇女中就有一名患有多囊卵巢综合症,这是一种终身的代谢紊乱疾病,找到减少其相关健康风险的方法是极其重要的。

拓展阅读

Genes & Diseases:Junli Liu/Yibing Wang教授团队总结肝因子在肥胖中的作用及其潜在的治疗意义

文章总结了肝因子在肥胖症中的作用及其在治疗干预中的潜在意义。

Nat Metab:难怪减肥这么难!肥胖让你的线粒体碎成渣,加速脂肪堆积

该研究证明,高脂肪饮食(HFD)喂养导致雄性小鼠腹股沟白色脂肪细胞线粒体断裂,导致氧化能力降低,这一过程依赖于小GTPase RalA。

CMI:复旦大学何睿/李华斌揭示肥胖个体对金黄色葡萄球菌更易感的潜在机理

该研究发现角化细胞中的趋化素-CMKLR1轴损害先天宿主对皮肤金黄色葡萄球菌感染的防御。

适合中国人的权威减肥食谱!最新指南:吃对5类食物很关键

医学营养治疗是肥胖治疗的基础,是在肥胖自然病程中任何阶段预防和控制必不可少的措施。

【热点解读】2023版NICE《肥胖:识别、评估和管理》解读:儿童、青少年与成人超重及肥胖识别与评估部分

该文对2023年英国国家卫生与临床优化研究所《肥胖:识别、评估和管理》中关于儿童、青少年与成人超重及肥胖的识别与评估进行解读,以期为超重及肥胖的综合评估提供简易参考。点击立即去下载。

香港浸会大学《自然·通讯》:研究显示青蒿素衍生物具备治疗人类肥胖潜力!

这是青蒿琥酯首次被证明能治疗非人类灵长类动物的肥胖,显示它成为治疗人类肥胖药物的潜力。

2024 意大利指南:成人超重、肥胖和代谢合并症行为治疗抵抗的管理

国外内分泌相关专家小组(统称) · 2024-04-17

2022 KSSO临床实践指南:儿童和青少年肥胖(更新版)

韩国肥胖研究学会(Korean Society for the Study of Obesity) · 2024-03-30

2024年世界肥胖报告

世界肥胖联盟 · 2024-04-05

儿童青少年肥胖食养指南(2024年版)

中华人民共和国国家卫生健康委员会 · 2024-02-08

成人肥胖食养指南(2024年版)

中华人民共和国国家卫生健康委员会 · 2024-02-08